🇺🇸 FDA
Patent

US 12171758

Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto

granted A61KA61K31/4709A61P

Quick answer

US patent 12171758 (Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto) held by Neumora Therapeutics, Inc. expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neumora Therapeutics, Inc.
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/4709, A61P, A61P25/06, A61P25/18